๎๊ฒ์
๎๊ฒ์
๎
Milestone Pharmaceuticals Inc
MIST๎ญ๊ด์ฌ ๋ชฉ๋ก์ ์ถ๊ฐ
1.505USD
-0.125-7.67%
์ข
๊ฐย 05/15, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
187.37M์๊ฐ์ด์ก
์์คP/E TTM
๎
์์ธํ ๋ด์ฉ์ Milestone Pharmaceuticals Inc ํ์ฌ
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Milestone Pharmaceuticals Inc ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ MIST
ํ์ฌ ์ด๋ฆMilestone Pharmaceuticals Inc
์์ฅ์ผMay 09, 2019
CEOOliveto (Joseph)
์ง์ ์33
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃMay 09
์ฃผ์420-1111 boul. Dr.-Frederik-Philips
๋์MONTREAL
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐCanada
์ฐํธ ๋ฒํธH4M 2X6
์ ํ15143360444
์น์ฌ์ดํธhttps://www.milestonepharma.com
์ข
๋ชฉ ์ฝ๋ MIST
์์ฅ์ผMay 09, 2019
CEOOliveto (Joseph)
Milestone Pharmaceuticals Inc์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+6.12%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+6.60%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+76.92%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
Mr. Lorenz Muller
Mr. Lorenz Muller
Chief Commercial Officer
Chief Commercial Officer
--
--
Mr. Seth H. Z. Fischer
Mr. Seth H. Z. Fischer
Independent Director
Independent Director
--
--
Mr. Jeffrey Nelson
Mr. Jeffrey Nelson
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Stuart Duty
Mr. Stuart Duty
Independent Director
Independent Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. David Bharucha
Dr. David Bharucha
Chief Medical Officer
Chief Medical Officer
128.30K
+6.12%
Mr. Amit Hasija
Mr. Amit Hasija
Chief Financial Officer, Executive Vice President - Corporate Development
Chief Financial Officer, Executive Vice President - Corporate Development
119.05K
+6.60%
Dr. Robert James Wills, Ph.D.
Dr. Robert James Wills, Ph.D.
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
65.00K
+76.92%
Mr. Michael John Tomsicek
Mr. Michael John Tomsicek
Independent Director
Independent Director
15.00K
--
Mr. Joseph Oliveto
Mr. Joseph Oliveto
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Lisa M. Giles
Ms. Lisa M. Giles
Independent Director
Independent Director
--
--
์์ต ๋ถ์
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฌ์
๋ณ
์ง์ญ๋ณ
๊ธฐ์
์ด ์์ง ๊ด๋ จ ๋ฐ์ดํฐ๋ฅผ ๊ณต๊ฐํ์ง ์์์ต๋๋ค.
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, May 14
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, May 14
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Simplify Asset Management Inc
4.70%
Propel Bio Management, LLC
4.28%
Adage Capital Management, L.P.
2.35%
Oliveto (Joseph Gerard)
2.18%
RTW Investments L.P.
2.09%
๊ธฐํ
84.39%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Simplify Asset Management Inc
4.70%
Propel Bio Management, LLC
4.28%
Adage Capital Management, L.P.
2.35%
Oliveto (Joseph Gerard)
2.18%
RTW Investments L.P.
2.09%
๊ธฐํ
84.39%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Investment Advisor
7.06%
Hedge Fund
6.74%
Investment Advisor/Hedge Fund
4.75%
Venture Capital
4.43%
Research Firm
2.80%
Individual Investor
2.79%
Family Office
0.85%
Bank and Trust
0.02%
๊ธฐํ
70.57%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Apr 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2026Q1
133
30.89M
25.86%
-18.70M
2025Q4
119
42.67M
50.10%
+14.57M
2025Q3
99
19.38M
22.80%
-5.64M
2025Q2
99
14.54M
18.86%
-15.65M
2025Q1
102
12.26M
22.94%
-17.24M
2024Q4
99
25.17M
47.19%
-9.38M
2024Q3
113
29.31M
55.02%
-13.44M
2024Q2
115
30.81M
57.87%
-11.80M
2024Q1
116
31.96M
60.43%
+3.19M
2023Q4
112
18.49M
55.02%
-13.59M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
Simplify Asset Management Inc
5.62M
4.78%
-2.33M
-29.32%
Dec 31, 2025
Propel Bio Management, LLC
5.12M
4.36%
+4.27M
+502.93%
Jul 11, 2025
Adage Capital Management, L.P.
2.81M
2.39%
-4.17M
-59.72%
Dec 31, 2025
Oliveto (Joseph Gerard)
2.65M
2.25%
-11.42K
-0.43%
Jan 26, 2026
RTW Investments L.P.
2.51M
2.13%
--
--
Dec 31, 2025
Two Sigma Investments, LP
2.13M
1.81%
+1.23M
+136.96%
Dec 31, 2025
Marshall Wace LLP
1.66M
1.41%
+1.23M
+289.81%
Dec 31, 2025
Lion Point Capital, L.P.
755.00K
0.64%
+96.45K
+14.65%
Dec 31, 2025
TD Securities, Inc.
750.00K
0.64%
--
--
Dec 31, 2025
Morgan Stanley & Co. LLC
731.54K
0.62%
-1.90M
-72.21%
Dec 31, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Dec 2
๋ง์ง๋ง ์
๋ฐ์ดํธ: Tue, Dec 2
์ด๋ฆ
๋น์จ
Simplify Propel Opportunities ETF
8.04%
SPDR S&P International Small Cap ETF
0.01%
Avantis US Small Cap Equity ETF
0%
Simplify Propel Opportunities ETF
๋น์จ8.04%
SPDR S&P International Small Cap ETF
๋น์จ0.01%
Avantis US Small Cap Equity ETF
๋น์จ0%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
๋ฐ์ดํฐ ์์
์ฃผ์ ๋ถํ
๎๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
๋ฐฐ๋น๋ฝ์ผ
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
